Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced new interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, focusing on 48 patients across three cohorts. Cohort 3, receiving 200 mg twice daily, showed earlier and deeper responses compared to cohorts 1 and 2. At day 28, cohort 3 demonstrated a 64.8% mean reduction in the Eczema Area and Severity Index $(EASI)$ score, compared to 54.6% for cohorts 1 and 2 combined, and 34.4% for the placebo group. The company has also initiated an extension cohort study exploring the cohort 3 dose over an 8-week period. Dr. Miller is set to present the findings at the Jefferies Global Healthcare Conference on June 5, 2025, with the presentation available via webcast on the Corvus website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.